NOVOTECH
28.8.2024 14:06:26 CEST | Business Wire | Press release
Novotech, a global full-service clinical Contract Research Organization (CRO), proudly announces its continued recognition as a Workplace Gender Equality Agency (WGEA) Employer of Choice for Gender Equality (EOCGE) in 2024. This marks another milestone in Novotech's ongoing commitment to fostering an inclusive and equitable workplace.
The EOCGE certification is a prestigious accolade in Australia's business landscape, acknowledging organizations that demonstrate exceptional dedication to achieving gender equality. This voluntary program recognizes employers who go above and beyond in creating an environment where all employees, regardless of gender, can thrive and succeed.
Novotech is one of only 81 companies that have held this award continually since 2023. Employers aiming to achieve the certification must demonstrate what they are doing to close their own gender pay gap, and through employee consultation, create policies and strategies to prevent sex-based harassment and discrimination, while setting targets for improving gender equality outcomes. They must account for their progress every two years.
Dr. John Moller, CEO of Novotech stated: "Receiving this re-certification in 2024 is a testament to our unwavering dedication to diversity and inclusion. It reflects the collective effort of our entire organization to champion these values. As we expand globally, we're committed to extending these best practices across all our operations, aiming to inspire positive change throughout our industry."
Angela Edwardson, Chief People Officer of Novotech added: "Our journey towards gender equality is an ongoing process deeply embedded in our corporate culture. The initiatives we've implemented as a WGEA Employer of Choice are not just policies on paper; they shape our daily operations, influence our strategic decisions, and contribute to a workplace environment that nurtures talent irrespective of gender."
Mary Wooldridge, CEO of WGEA: “In taking action to improve gender equality, EOCGE employers unlock enormous benefits for their business. Employees are more likely to join and to stay in organizations that prioritize a culture of equality and inclusion. Research also shows that businesses with greater gender balance in leadership roles are more profitable and productive.”
Novotech stands out among the select group of Australian employers in maintaining this prestigious citation, showcasing its sustained commitment to gender equality. As the company continues to grow and evolve, its dedication to creating an inclusive, diverse, and equitable workplace remains at the forefront of its organizational values, positively impacting the lives and careers of our employees.
The WGEA Employer of Choice for Gender Equality citation reaffirms Novotech's position as a leader in workplace equality. It not only sets a benchmark for the biotech and CRO sectors in Australia and internationally but also inspires others to follow suit, making us all proud to be a leader of this positive change in our industry.
About Novotech Novotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
Background: The WGEA EOCGE citation
Criteria for the citation cover leadership, learning and development, gender pay gaps, flexible working and other initiatives to support family responsibilities.
The criteria also ask employers about employee consultation, policies and strategies to prevent sex-based harassment and discrimination, and targets for improving gender equality outcomes.
Employers must demonstrate what they are doing to close their own gender pay gap by conducting an annual analysis of what’s driving their gender pay gap and following up on this by setting targets and identifying actions to reduce it. They must account for their progress every 2 years.
The Agency’s certification process also requires employee confirmation that there’s a zero-tolerance approach to gender-based harassment and sexual harassment, and that managers genuinely create environments within their teams that support equality for all employees.
The criteria are regularly strengthened to reflect best practice.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240826774489/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global udvider sin juridiske virksomhed i Pakistan med et nyt medlemsfirma2.10.2026 22:36:00 CEST | Pressemeddelelse
Andersen Global styrker sin juridiske tilstedeværelse i Pakistan, idet Samdani & Qureshi, der har været samarbejdspartner siden 2021, skifter navn til Andersen Legal in Pakistan og bliver den seneste medlemsvirksomhed, der slutter sig til organisationen. Andersen Legal in Pakistan har hovedkontor i Islamabad og rådgiver både indenlandske og internationale klienter, herunder virksomheder, investorer, finansielle institutioner, offentlige enheder, udviklingsorganisationer og privatpersoner, om juridiske, kommercielle og regulatoriske forhold. Firmaet arbejder også med voldgift og tvistbilæggelse og rådgiver om komplekse transaktioner, investeringer, finansiering, projekter og tvister i Pakistan og på tværs af landegrænser. "Vores tilgang bygger på stærkt engagement fra ledelsen, klar kommunikation og disciplineret analyse med fokus på at levere rådgivning, som vores klienter kan omsætte til handling," sagde Nudrat Ejaz Piracha, partner hos Andersen Legal in Pakistan. "Ved at blive en del
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 17:12:00 CEST | Press release
Appointments expand emnify executive team to accelerate global growth emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 15:00:00 CEST | Press release
Enterprise software veteran to lead Tacton’s united commercial organization and partner expansion worldwide. Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 15:00:00 CEST | Press release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 14:00:00 CEST | Press release
Intranasal pertussis vaccine candidate BPZE1 demonstrates robust nasal mucosal and systemic immune responses with a favorable safety profile in children ages 6 through 17 yearsFirst pediatric clinical trial builds on 5 prior adult BPZE1 clinical studiesDemonstrates safety and immunogenicity of BPZE1 in acellular pertussis vaccine primed individualsNo interference observed when BPZE1 co-administered with diphtheria and tetanus antigens ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The stu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
